New Trial Alert: Alliance A222001 Hot Flash Treatment for Men with Prostate Cancer

July 30, 2021

Alliance A222001: A randomized, double-blind, placebo-controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy

Overview: Alliance investigator Bradley Stish, MD, of Mayo Clinic, leads this phase II trial that compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen de

Sanofi Partnering with Leading Academic Cooperative Groups to Study Amcenestrant in the Adjuvant Setting for Patients with Estrogen Receptor Positive Breast Cancer

June 4, 2021

  • Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research
  • Collaborating on the P

It's a Wrap: 2021 Alliance Spring Virtual Group Meeting

May 18, 2021

THANK YOU to everyone who participated in the 2021 Alliance Spring Virtual Group Meeting. Your amazing efforts continue to advance cancer research. Our next Group meeting will be held in person in Chicago November 4-6 2021. Unitl then, stay safe and well!

Be sure to check the Meeting Presentations section of this website beginning the week of May 25 for videos and slide decks from meeting sessions. In the me

Older News